A Phase 3 interventional study of Piroxicam plus Counterirritant (brand name Counterpain® PXM). and Diclofenac Sodium 10 mg (Brand Name Hotin® DCL) in Ankle Sprain, Back Pain and Osteoarthritis (OA) of the Knee, sponsored by Taisho Pharmaceutical Indonesia. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Taisho Pharmaceutical Indonesia (part of Taisho Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if a gel containing Piroxicam plus Counterirritant (warming/cooling ingredients) is as effective and safe as two other common anti-inflammatory gels for treating acute muscle, bone, and joint pain in adults aged 18-60. The main questions it aims to answer are:
Does the Piroxicam plus Counterirritant gel provide a similar level of pain relief as the standard Piroxicam-only gel and the Diclofenac gel?
Is the Piroxicam plus Counterirritant gel as safe to use as the other two gels?
Researchers will compare three groups of participants, each using one of the gels (Piroxicam plus Counterirritant, Piroxicam-only, or Diclofenac) to see if the combination gel works equally well.
Participants will:
The primary goal is to demonstrate that a gel containing the active ingredients Piroxicam plus Counterirritant is equally effective and safe as two other widely used gels in reducing pain. The three gels being compared are:
Comparator Gel B: Diclofenac gel (brand name Hotin® DCL). This is another very common and well-studied anti-inflammatory gel, often considered a standard treatment for this type of pain.
The study's central hypothesis is that the Piroxicam-plus-counterirritant gel is not inferior to the other two and provides a similar level of pain relief and safety. This type of study is called an equivalence trial.
How is the Study Designed?
This is a Phase 3, Randomized, Controlled, Multi-center, Single-blind, Parallel-group study. Here's what each of these terms means:
How Long Will the Study Last for Each Person?
The total duration of participation for each individual is 6 ± 1 days. This means the study period could be anywhere from 5 to 7 days. During this time, participants will need to visit the clinic three times:
Who Can Take Part in the Study? (Inclusion and Exclusion Criteria) To ensure the study is fair, safe, and that the results are clear and reliable, only people who meet very specific requirements can participate.
Inclusion Criteria (who can join):
- Outpatients at one of the two study clinics.
Exclusion Criteria (who cannot join):
What Will Happen During the Study Visits? The process is carefully structured for each of the three visits. This ensures consistency and that all necessary data is collected correctly.
Visit 1 (Day 0 - The Start):
Registration \& Screening: A person with pain registers at the clinic. The research team explains the study in detail. If interested, the participant reads and signs the Informed Consent Form, a document confirming they understand the study and voluntarily agree to take part.
Initial Assessments:
Take-Home Kit: The participant is given a pouch containing everything they need for the next few days:
- 2 tubes of their assigned study gel.
- 3 dosing cards (to help measure the correct amount of gel each time).
- 4 strips of rescue medication (paracetamol 600mg tablets).
- A participant diary to record gel applications, pain levels, and any other medications taken. Business cards for the study coordinator and doctor.
At Home (Between Visits):
- The participant applies the gel at home three times a day (morning, afternoon, evening) using the dosing card.
- They record each application and any changes in their pain in the diary.
- The study coordinator will send daily reminders (e.g., by phone or text) to help with compliance.
- If the pain becomes unbearable, the participant can take the paracetamol (rescue medication) and must record the date and time in the diary.
Visit 2 (Day 3 ± 1 day - The Midpoint):
- The participant returns to the clinic, bringing back their pouch with all remaining products and their completed diary.
- They re-register and meet with the doctor. The same assessments from Visit 1 are repeated (pain questionnaires, ROM, muscle strength).
Visit 3 (Day 6 ± 1 day - The End):
353 studies on the registry are indexed under Ankle Injuries; 74 are open to participants now.
This study's enrollment of 180 is above the median of 54 across 271 interventional studies indexed under Ankle Injuries.
Browse Ankle Injuries studies →Taisho Pharmaceutical Indonesia is the lead sponsor of 2 studies on the registry; none are open to participants now.
First submitted after Taisho Pharmaceutical Indonesia became part of Taisho Pharmaceutical Co., Ltd..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apply gel to the affected area three times daily leaving no residual material on the skin.1 gram of gel ( \~ 3 cm) applied to the affected area.
Drug: Piroxicam plus Counterirritant (brand name Counterpain® PXM).
Apply gel to the affected area three times daily leaving no residualmaterial on the skin. 1 gram of gel ( \~ 3 cm) applied to the affected area.
Drug: Diclofenac Sodium 10 mg (Brand Name Hotin® DCL) · Drug: Piroxicam 0.5% (Brand name Pirofel® gel)
Participants assigned to this intervention group will use Piroxicam plus Counterirritant gel (Counterpain® PXM) . Each application involves dispensing approximately 1 gram (3 cm) of gel onto a provided dosing card and applying it directly to the painful area. The gel contains 0.5% Piroxicam as the anti-inflammatory agent, combined with three counterirritants: Methyl Salicylate, Menthol, and Eugenol. These counterirritants produce distinct warming and cooling sensations upon application. Participants will apply the gel three times daily (morning, afternoon, evening) for 6 ± 1 days. The total number of applications and the timing of the perceived thermal sensation will be recorded in a participant diary. This intervention is distinct from the comparator arms (Piroxicam-only and Diclofenac gels) specifically due to the presence of these counterirritant ingredients, which are intended to provide additional symptomatic relief through sensory stimulation.
Dose : Refer to the product's leaflet : no occlusive dress should be employed. Apply the required amount of cream on the affected area three times a day and rub gently. The amount of cream needed depends on the extent of the painful area. The affected area are : * In the arms: hand, wrist, elbow, shoulder sinistra or dextra * In the legs: feet, ankle, knee sinistra or dextra * Upper back or Lower back 3 times daily means : * application one time in morning (06.00 - 11.00), o one time in afternoon (11.01 - 17.00), * one time in evening (17.01 - 23.00). Aplication of gel will use dosing card that provided in this clinical study. * Method of administration: external use only. * Every visit, participants will get 2 tubes and in total are 6 tubes for 6 + 1 days application
Dose: Apply gel to the affected area three times daily leaving no residual material on the skin. 1 gram of gel applied to the affected area. The affected area are : * In the arms: hand, wrist, elbow, shoulder sinistra or dextra * In the legs: feet, ankle, knee sinistra or dextra * Upper back or Lower back 3 times daily means : * application one time in morning (06.00 - 11.00) * one time in afternoon (11.01 - 17.00), * one time in evening (17.01 - 23.00). Aplication of gel will use dosing card that provided in this clinical study. * Method of administration: external use only. * Every visit, participants will get 2 tubes and in total are 6 tubes for 6 + 1 days application.
The primary end-point is the difference of musculoskeletal pain reduction > 3 scores , of the response to treatment that can be seen through Brief Pain Inventory (BPI) scores.
The Brief Pain Inventory (BPI) scores is a medical questionnaire that is used to assess pain. It has also been validated for pain assessment chronicle. There are 9 questions related to the pain experienced by the participants. The pain assessment will be given in the form of a score, namely a score of 0 - 10. The difference BPI scale \> 3 , from initial scale of pain to the end of treatment will be captured as the primary efficacy endpoint. The selection of difference more than equal to 3 was chosen because if the participant has moderate pain at the beginning of the treatment, then at the end of the treatment there is a decrease in pain to mild pain. This can be seen that the treatment is effective in dealing with musculoskeletal pain
Time frame: From enrollment to the end of treatment at 4 months
Ran from Nov 2025 to primary completion in Feb 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.